Novavax has agreed to participate in the University of Oxford’s Com-COV2 study evaluating the safety and efficacy of regimens consisting of doses of COVID-19 vaccines from different manufacturers.
List view / Grid view
Filter the results
The FDA and CDC have decided to temporarily suspend use of Janssen’s single dose vaccine while reports of rare and severe blood clots are investigated.
The trial will evaluate the safety and immunogenicity of the mRNA-1273.351 vaccine candidate in 200 healthy adult volunteers.
The European Medicines Agency has published its recommendations for 2021-2022 seasonal influenza vaccine composition.
The African Vaccine Acquisition Trust (AVAT) has entered into an advanced purchase agreement for 220 million doses of Janssen COVID-19 Vaccine.
Following DSMB concerns about the data released regarding the Phase III US trial, AstraZeneca has now confirmed that its vaccine is 76 percent effective against symptomatic COVID-19.
The submission is the first in a series that will include dengue-endemic countries, it includes long-term Phase III safety and efficacy data for the TAK-003 vaccine candidate.
According to GlobalData, AstraZeneca’s and Janssen’s COVID-19 vaccines could be impacted by global viral vector shortages.
An analysis of results from 20,000 vaccinnees shows AstraZeneca’s vaccine completely prevents severe or critical COVID-19 and hospitalisation.
MIT researchers developed and tested in mice intratracheal vaccines to protect against the vaccinia virus and the formation of lung cancer.
The Phase II/III trial will assess the safety and efficacy of the COVID-19 Vaccine Moderna in children aged six months to less than 12 years.
The Janssen COVID-19 Vaccine is the first single-dose vaccine regimen to ever be granted WHO emergency use listing and is now eligible for distribution via COVAX.
New trial data shows Novavax’s COVID-19 vaccine, NVX–CoV2373, is effective against both the B.1.1.7 UK and the B1.351 South African variants.
New research shows a second COVID-19 vaccine dose may be unnecessary in individuals previously infected with SARS-CoV-2 and needlessly exposes individuals to higher rates of adverse effects.
Moderna has begun testing two new mRNA COVID-19 vaccines, one specifically targeting the B.1.351 variant and the other a multivalent candidate.